{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:55:11Z","timestamp":1782125711581,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ejca.2015.12.013","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T21:25:19Z","timestamp":1453238719000},"page":"31-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients"],"prefix":"10.1016","volume":"56","author":[{"given":"A.","family":"Lintermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Van Asten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Van Brussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Verhaeghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vanderschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2015.12.013_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10549-014-2986-7","article-title":"A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI","volume":"146","author":"Lintermans","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2015.12.013_bib2","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","article-title":"Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer","volume":"30","author":"Henry","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.12.013_bib3","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.24419","article-title":"Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors","volume":"115","author":"Mao","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2015.12.013_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4174\/jkss.2013.85.5.205","article-title":"Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors","volume":"85","author":"Park","year":"2013","journal-title":"J Korean Surg Soc"},{"key":"10.1016\/j.ejca.2015.12.013_bib5","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/acr.21756","article-title":"Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study","volume":"64","author":"Singer","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ejca.2015.12.013_bib6","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S1470-2045(08)70182-7","article-title":"Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis","volume":"9","author":"Sestak","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2015.12.013_bib7","doi-asserted-by":"crossref","first-page":"11071","DOI":"10.1158\/0008-5472.CAN-05-1218","article-title":"Human aromatase: gene resequencing and functional genomics","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2015.12.013_bib8","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr2813","article-title":"Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors","volume":"13","author":"Mao","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2015.12.013_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10549-013-2638-3","article-title":"Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study","volume":"140","author":"Garcia-Giralt","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2015.12.013_bib10","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/0008-5472.CAN-06-4123","article-title":"Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women","volume":"67","author":"Haiman","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2015.12.013_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10549-013-2504-3","article-title":"Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer","volume":"138","author":"Henry","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2015.12.013_bib12","first-page":"925","article-title":"Review of the declaration of Helsinki","volume":"227","author":"World Medical Association","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2015.12.013_bib13","series-title":"Correlation between gene variants in CYP19 (aromatase) and TCL1A with disease and tolerability endpoints in the ATAC trial","author":"Rae","year":"2011"},{"key":"10.1016\/j.ejca.2015.12.013_bib14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00280-011-1615-y","article-title":"Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer","volume":"68","author":"Park","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2015.12.013_bib15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-014-2873-2","article-title":"Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial","volume":"144","author":"Fontein","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2015.12.013_bib16","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1210\/jc.2006-1616","article-title":"Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis","volume":"92","author":"Riancho","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2015.12.013_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/1055-9965.EPI-03-0026","article-title":"Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women","volume":"13","author":"Tworoger","year":"2004","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ejca.2015.12.013_bib18","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1200\/JCO.2010.28.5064","article-title":"Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors","volume":"28","author":"Ingle","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.12.013_bib19","doi-asserted-by":"crossref","first-page":"e68798","DOI":"10.1371\/journal.pone.0068798","article-title":"Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2015.12.013_bib20","doi-asserted-by":"crossref","first-page":"e1002805","DOI":"10.1371\/journal.pgen.1002805","article-title":"A genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid hormone regulation","volume":"8","author":"Coviello","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ejca.2015.12.013_bib21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.canep.2012.04.006","article-title":"Selected polymorphisms in sex hormone-related genes, circulating sex hormones and risk of endometrial cancer","volume":"36","author":"Lundin","year":"2012","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.ejca.2015.12.013_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/eje.1.02318","article-title":"Adiposity, estradiol, and genetic variants of steroid-metabolizing enzymes as determinants of bone mineral density","volume":"156","author":"Zarrabeitia","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejca.2015.12.013_bib23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1210\/me.2012-1397","article-title":"TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression","volume":"27","author":"Liu","year":"2013","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ejca.2015.12.013_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/MB:26:2:147","article-title":"MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis","volume":"26","author":"Jurinke","year":"2004","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.ejca.2015.12.013_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B"},{"key":"10.1016\/j.ejca.2015.12.013_bib26","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1210\/jc.2007-1019","article-title":"Osteoprotegerin Lys3Asn polymorphism and the risk of fracture in older women","volume":"93","author":"Moffett","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2015.12.013_bib27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1359\/jbmr.2002.17.7.1245","article-title":"Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures","volume":"17","author":"Langdahl","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2015.12.013_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/rheumatology\/keg047","article-title":"Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls","volume":"42","author":"Haynes","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejca.2015.12.013_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3816\/CBC.2009.n.006","article-title":"Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?","volume":"9","author":"Muslimani","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejca.2015.12.013_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/dna.2013.2206","article-title":"Association between seven common OPG genetic polymorphisms and osteoporosis risk: a meta-analysis","volume":"33","author":"Guo","year":"2014","journal-title":"DNA Cell Biol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915011570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915011570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T21:47:24Z","timestamp":1718315244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915011570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":30,"alternative-id":["S0959804915011570"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.12.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}